Pharmaceutical Technology2d
Talimogene laherparepvec by Amgen for Soft Tissue Sarcoma: Likelihood of Approval
Talimogene laherparepvec is under clinical development by Amgen and currently in Phase II for Soft Tissue Sarcoma.
Pharmaceutical Technology2d
Dostarlimab by GSK for Soft Tissue Sarcoma: Likelihood of Approval
Dostarlimab is under clinical development by GSK and currently in Phase II for Soft Tissue Sarcoma. According to GlobalData, Phase II drugs for Soft Tissue Sarcoma have a 26% phase transition success ...